RapIT tested a single-visit ART initiation approach that significantly increased the proportion of patients starting ART within 90 days compared to standard of care. However, it relied on expensive point-of-care tests. SLATE aims to evaluate a simplified algorithm without these tests to determine immediate ART eligibility and initiate treatment in a single visit, with the goals of increasing prompt ART uptake and evaluating its costs and patient outcomes compared to standard care. If successful, SLATE could help standardize a fast, effective, and low-cost ART initiation model to strengthen the testing to treatment cascade.
Brief Interventions for alcohol problems. OECD meeting.Antoni Gual
Lecture on efficacy & effectiveness of Brief Interventions for Alcohol problems, given in to the OECD - HEALTH COMMITTEE, 16th Session.PARIS, DECEMBER 9th, 2014
Providing actionable healthcare analytics at scale: Insights from the Nationa...Nuffield Trust
Christopher Boulton, Falls and Fragility Fracture Audit Programme Manager at the Royal College of Physicians and Rob Wakeman, Clinical Lead for Orthopaedic Surgery at the National Hip Fracture Database talk about what they have learned by analysing the national hip fracture database.
Evaluating new models of care: Improvement Analytics UnitNuffield Trust
Martin Caunt, Improvement Analytics Unit Project Director and NHS England and Adam Steventon, Director of Data Analytics at The Health Foundation share insights into how they have approached evaluating new models of care.
Providing actionable healthcare analytics at scale: Understanding improvement...Nuffield Trust
Thomas Woodcock, Improvement Science Fellow at Imperial College London, talks about the various measurement approaches and processes when working at large scale to assess care quality improvements.
Expert Panelists: Dr. Jason Reed, Biomedical HIV Prevention
Technical Advisor, Jhpiego & Dr. More Mungati, STAR-L Director, EGPAF, Lesotho
Moderator: Dr. Seema Ntjabane, Care & Treament Specialist, USAID-Lesotho
Expert panelists:
Dr. Tafadzwa Chakare, Technical Director, Jhpiego, Lesotho
Dr. More Mungati, STAR-L Director, EGPAF Lesotho
Facilitator:
Dr. Seema Ntjabane, Care & Treatment Specialist, USAID-Lesotho
Martin Utley, Director of the Clinical Operational Research Unit at University College London, reflects upon his involvement in the launch of specific tools to monitor care quality for paediatric cardiac surgery.
Paul Aylin, Co-Director of the Dr Foster Unit at Imperial College London, gives concrete examples of using a specific statistical model for monitoring care quality, cumulative sum (CUSUM).
Brief Interventions for alcohol problems. OECD meeting.Antoni Gual
Lecture on efficacy & effectiveness of Brief Interventions for Alcohol problems, given in to the OECD - HEALTH COMMITTEE, 16th Session.PARIS, DECEMBER 9th, 2014
Providing actionable healthcare analytics at scale: Insights from the Nationa...Nuffield Trust
Christopher Boulton, Falls and Fragility Fracture Audit Programme Manager at the Royal College of Physicians and Rob Wakeman, Clinical Lead for Orthopaedic Surgery at the National Hip Fracture Database talk about what they have learned by analysing the national hip fracture database.
Evaluating new models of care: Improvement Analytics UnitNuffield Trust
Martin Caunt, Improvement Analytics Unit Project Director and NHS England and Adam Steventon, Director of Data Analytics at The Health Foundation share insights into how they have approached evaluating new models of care.
Providing actionable healthcare analytics at scale: Understanding improvement...Nuffield Trust
Thomas Woodcock, Improvement Science Fellow at Imperial College London, talks about the various measurement approaches and processes when working at large scale to assess care quality improvements.
Expert Panelists: Dr. Jason Reed, Biomedical HIV Prevention
Technical Advisor, Jhpiego & Dr. More Mungati, STAR-L Director, EGPAF, Lesotho
Moderator: Dr. Seema Ntjabane, Care & Treament Specialist, USAID-Lesotho
Expert panelists:
Dr. Tafadzwa Chakare, Technical Director, Jhpiego, Lesotho
Dr. More Mungati, STAR-L Director, EGPAF Lesotho
Facilitator:
Dr. Seema Ntjabane, Care & Treatment Specialist, USAID-Lesotho
Martin Utley, Director of the Clinical Operational Research Unit at University College London, reflects upon his involvement in the launch of specific tools to monitor care quality for paediatric cardiac surgery.
Paul Aylin, Co-Director of the Dr Foster Unit at Imperial College London, gives concrete examples of using a specific statistical model for monitoring care quality, cumulative sum (CUSUM).
Introduction of the NZ Health IT Plan enables better gout management - Reflections of an early adopter. Presented by Peter Gow, Counties Manukau DHB, at HINZ 2014, 12 November 2014, 11.37am, Plenary Room
Engage and Retain Patients in Long-term Observational StudiesJohn Reites
Traditionally, real-world and late phase studies require sites to enroll, engage and retain patients and collect and record patient reported outcomes (PRO), which can be burdensome to both sites and patients. Overtime, sites and patients may lose motivation to participate, contributing to high patient dropout rates, increased study costs and site dissatisfaction. This session will focus on innovative approaches for effectively engaging and retaining patients in long-term studies, such as: identifying design and operational considerations with conducting long-term observational research, understanding site and patient retention challenges, and examining engagement strategies and opportunities for improving retention and compliance.
Opening Keynote"From Patient to Population: Providing Optimal Care - The Role for Technology"
Ronald Paulus, MD, MBA
President & CEO
Mission Health System
Presentation by Dr Martin Myers MBE, PhD, FRCPath, Consultant Clinical Biochemist, Lancashire Teaching Hospitals NHS Foundation Trust at ECO 19: Care closer to home on Tuesday 9 July at Deepdale Stadium.
Expediting Colonoscopy for Patients with + Faecal Occult Blood Test in a Publ...Cancer Institute NSW
Colon cancer is the commonest cancer in Australia. The Federal Gov. has recently accelerated the rollout of the National Bowel Cancer Screening Program to 2nd yearly after age 50 by 2018. We anticipate up to 1000 extra colonoscopies on the public system at NSLHD.
Kate Silvester, a healthcare systems engineer, discusses the challenges of working with data and statistical techniques for real-time monitoring of care quality.
Discover more about how the West of England AHSN is putting innovation at the heart of healthcare, improving patient outcomes and generating wealth for economic growth.
Clinicians Satisfaction Before and After Transition from a Basic to a Compreh...Allison McCoy
Healthcare organizations are transitioning from basic to comprehensive electronic health records (EHRs) to meet Meaningful Use requirements and improve patient safety. Yet, full adoption of EHRs is lagging and may be linked to clinician dissatisfaction. In depth assessment of satisfaction before, during, and after EHR transition is rarely done. Using an adapted published tool to assess adoption and satisfaction with EHRs, we surveyed clinicians at a large, non-profit academic medical center before (baseline) and 6-12 months (short-term follow-up) and 12-24 months (long-term follow-up) after transition from a basic, locally-developed to a comprehensive, commercial EHR. Satisfaction with the EHR (overall and by component) was captured at each interval. Overall satisfaction was highest at baseline (85%), lowest at short-term follow-up (66%), and increasing at long-term follow-up (79%). This trend was similar for satisfaction with EHR components designed to improve patient safety including clinical decision support, patient communication, health information exchange, and system reliability. Conversely, at baseline, short-term and long-term follow-up, perceptions of productivity, ability to provide better care with the EHR, and satisfaction with available resources, were lower at both short- and long-term follow-up compared to baseline. Persistent dissatisfaction with productivity and resources was identified. Addressing determinants of dissatisfaction may increase full adoption of EHRs. Further investigation in larger populations is warranted.
Introduction of the NZ Health IT Plan enables better gout management - Reflections of an early adopter. Presented by Peter Gow, Counties Manukau DHB, at HINZ 2014, 12 November 2014, 11.37am, Plenary Room
Engage and Retain Patients in Long-term Observational StudiesJohn Reites
Traditionally, real-world and late phase studies require sites to enroll, engage and retain patients and collect and record patient reported outcomes (PRO), which can be burdensome to both sites and patients. Overtime, sites and patients may lose motivation to participate, contributing to high patient dropout rates, increased study costs and site dissatisfaction. This session will focus on innovative approaches for effectively engaging and retaining patients in long-term studies, such as: identifying design and operational considerations with conducting long-term observational research, understanding site and patient retention challenges, and examining engagement strategies and opportunities for improving retention and compliance.
Opening Keynote"From Patient to Population: Providing Optimal Care - The Role for Technology"
Ronald Paulus, MD, MBA
President & CEO
Mission Health System
Presentation by Dr Martin Myers MBE, PhD, FRCPath, Consultant Clinical Biochemist, Lancashire Teaching Hospitals NHS Foundation Trust at ECO 19: Care closer to home on Tuesday 9 July at Deepdale Stadium.
Expediting Colonoscopy for Patients with + Faecal Occult Blood Test in a Publ...Cancer Institute NSW
Colon cancer is the commonest cancer in Australia. The Federal Gov. has recently accelerated the rollout of the National Bowel Cancer Screening Program to 2nd yearly after age 50 by 2018. We anticipate up to 1000 extra colonoscopies on the public system at NSLHD.
Kate Silvester, a healthcare systems engineer, discusses the challenges of working with data and statistical techniques for real-time monitoring of care quality.
Discover more about how the West of England AHSN is putting innovation at the heart of healthcare, improving patient outcomes and generating wealth for economic growth.
Clinicians Satisfaction Before and After Transition from a Basic to a Compreh...Allison McCoy
Healthcare organizations are transitioning from basic to comprehensive electronic health records (EHRs) to meet Meaningful Use requirements and improve patient safety. Yet, full adoption of EHRs is lagging and may be linked to clinician dissatisfaction. In depth assessment of satisfaction before, during, and after EHR transition is rarely done. Using an adapted published tool to assess adoption and satisfaction with EHRs, we surveyed clinicians at a large, non-profit academic medical center before (baseline) and 6-12 months (short-term follow-up) and 12-24 months (long-term follow-up) after transition from a basic, locally-developed to a comprehensive, commercial EHR. Satisfaction with the EHR (overall and by component) was captured at each interval. Overall satisfaction was highest at baseline (85%), lowest at short-term follow-up (66%), and increasing at long-term follow-up (79%). This trend was similar for satisfaction with EHR components designed to improve patient safety including clinical decision support, patient communication, health information exchange, and system reliability. Conversely, at baseline, short-term and long-term follow-up, perceptions of productivity, ability to provide better care with the EHR, and satisfaction with available resources, were lower at both short- and long-term follow-up compared to baseline. Persistent dissatisfaction with productivity and resources was identified. Addressing determinants of dissatisfaction may increase full adoption of EHRs. Further investigation in larger populations is warranted.
The Flu-FIT Program : An Effective Colorectal Cancer Screening Intervention
Présentation de Michael B. Potter au colloque "Recherche interventionnelle contre le cancer : Réunir chercheurs, décideurs et acteurs de terrain » - 17 et 18 novembre 2014, BnF, Paris
TYA and Adult Late Effects Service at UCLHUCLPartners
Presentation by Victoria Grandage of University College London Hospitals NHS Foundation Trust at the London Cancer Children, Teenager and Young Adults Study Day, held on 25 July 2013.
Objective
Safer Healthcare Now!, a program of the Canadian Patient Safety Institute, invites you to participate in the Canadian VTE Audit, designed to establish a national perspective of VTE thromboprophylaxis rates and raise awareness of appropriate VTE prophylaxis.
VTE is one of the most common and preventable complications of hospitalization and is a Required Organizational Practice (ROP) of Accreditation Canada.
By participating in the national audit day you will be a part of a movement aimed at preventing deep vein thrombosis (DVT) and pulmonary embolism (PE) in hospital patients.
Watch the recording: http://bit.ly/1wfinCE
Evaluation of the Impact of a Social Support Strategy on Treatment OutcomesMEASURE Evaluation
Shared at a data dissemination and data use workshop on the results of the impact evaluation of the Strengthening Tuberculosis Control in Ukraine project. Access another presentation at https://www.slideshare.net/measureevaluation/evaluation-of-the-tbhiv-integration-strategy-on-treatment-outcomes.
Similar to Operational research to increase the efficiency of ART initiation in Africa (20)
Trauma Outpatient Center is a comprehensive facility dedicated to addressing mental health challenges and providing medication-assisted treatment. We offer a diverse range of services aimed at assisting individuals in overcoming addiction, mental health disorders, and related obstacles. Our team consists of seasoned professionals who are both experienced and compassionate, committed to delivering the highest standard of care to our clients. By utilizing evidence-based treatment methods, we strive to help our clients achieve their goals and lead healthier, more fulfilling lives.
Our mission is to provide a safe and supportive environment where our clients can receive the highest quality of care. We are dedicated to assisting our clients in reaching their objectives and improving their overall well-being. We prioritize our clients' needs and individualize treatment plans to ensure they receive tailored care. Our approach is rooted in evidence-based practices proven effective in treating addiction and mental health disorders.
ICH Guidelines for Pharmacovigilance.pdfNEHA GUPTA
The "ICH Guidelines for Pharmacovigilance" PDF provides a comprehensive overview of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines related to pharmacovigilance. These guidelines aim to ensure that drugs are safe and effective for patients by monitoring and assessing adverse effects, ensuring proper reporting systems, and improving risk management practices. The document is essential for professionals in the pharmaceutical industry, regulatory authorities, and healthcare providers, offering detailed procedures and standards for pharmacovigilance activities to enhance drug safety and protect public health.
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
COVID-19 PCR tests remain a critical component of safe and responsible travel in 2024. They ensure compliance with international travel regulations, help detect and control the spread of new variants, protect vulnerable populations, and provide peace of mind. As we continue to navigate the complexities of global travel during the pandemic, PCR testing stands as a key measure to keep everyone safe and healthy. Whether you are planning a business trip, a family vacation, or an international adventure, incorporating PCR testing into your travel plans is a prudent and necessary step. Visit us at https://www.globaltravelclinics.com/
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...The Lifesciences Magazine
Deep Leg Vein Thrombosis occurs when a blood clot forms in one or more of the deep veins in the legs. These clots can impede blood flow, leading to severe complications.
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
PET CT beginners Guide covers some of the underrepresented topics in PET CTMiadAlsulami
This lecture briefly covers some of the underrepresented topics in Molecular imaging with cases , such as:
- Primary pleural tumors and pleural metastases.
- Distinguishing between MPM and Talc Pleurodesis.
- Urological tumors.
- The role of FDG PET in NET.
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
This document is designed as an introductory to medical students,nursing students,midwives or other healthcare trainees to improve their understanding about how health system in Sri Lanka cares children health.
Operational research to increase the efficiency of ART initiation in Africa
1. Operational Research to Increase the Efficiency
of Antiretroviral Therapy Initiation in Africa
Sydney Rosen
Department of Global Health
Boston University School of Public Health
Health Economics and Epidemiology Research Office,
University of the Witwatersrand
February 1, 2017
2. Today’s talk:
• The problem: Inefficient ART initiation
• A solution: RapIT
• The problem with the solution: Cost and cost-effectiveness
• A new solution: SLATE
4. A “Treat All” World
• In mid-2015, the World Health Organization recommended
offering ART to all HIV-positive persons, with no eligibility
threshold: “Treat All”
• By the end of 2016, nearly all African countries had
adopted treat all into national policy
• Currently (2015): 12 million people on ART in Africa (UNAIDS Fact
Sheet November 2016)
• UNAIDS elimination target for 2030: 24 million people on ART
• “90-90-90” target for 2020: 15-16 million people on ART (WHO
Global Health Observatory 2017)
• Upshot is that we have to start a lot more patients on ART
in the next decade
1 National Department of Health 2013; 2Plazy et al 2014; 3Clouse et al 2013; 4Rosen and Fox 2011; 5Larson et al 2010
5. What if the patients won’t start?
• Even after being found eligible for ART, patients don’t start treatment
when they should:
- 57% of treatment-eligible patients didn’t start treatment ≤ 6 months in
KwaZulu Natal Province in South Africa in 2011-2012
- The probability of starting ART < 6 months was lowest in those with
highest CD4 counts (Bor et al 2017, under review)
• Instead, patients wait until their CD4 counts fall and they are sick
- In South Africa, >50% started with CD4 count <270 in 2015 (Boulle et al
2015)
• In a “treat all” world, everyone with HIV is eligible for ART and many
will be diagnosed with high CD4 counts
• Our best strategy for expanding early treatment uptake could be to
expand testing and initiate ART immediately after a positive HIV test,
before the patient leaves the testing site (true “test and treat”)
1 National Department of Health 2013; 2Plazy et al 2014; 3Clouse et al 2013; 4Rosen and Fox 2011; 5Larson et al 2010
6. Why don’t people start ART?
• HIV test; result positive
• Give blood sample for CD4 count
• Complete TB symptom screen
• Provide sputum sample if symptomatic
Visit 1
• Provide CD4 count results; treatment eligible
• Provide TB test results and initiate TB treatment if
required
Visit 2
• Individual counseling session (education/adherence)Visit 3
• Group counseling session (education/adherence)Visit 4
• Provide results of other blood tests
• Treatment buddy session
Visit 5
• Conduct physical examination
• Dispense ARVs
Visit 6
I am
exhausted
…
Many reasons, but one is that starting treatment is not easy. The process has
traditionally been slow, resource-intensive, and grueling for patients. For example,
in South Africa…
8. RapIT: Rapid Initiation of Treatment
Individually randomized, controlled trial of single-visit (“same
day”) ART initiation compared to standard of care initiation in
Johannesburg, South Africa
Randomized (1:1) 377 adult, non-pregnant patients after positive
HIV test or first CD4 count to rapid or standard initiation arms
Intervention:
Compressed and accelerated initiation procedures to allow all steps
to be completed in one clinic visit
Used rapid, point-of care laboratory tests at point of care for
immediate determination of treatment eligibility and regimen choice
Outcomes: ART initiation by 90 days; initiated by 90 days and
retained and suppressed by 10 months
Follow up by chart review until July 2015
• Take blood sample for CD4 count and perform rapid
CD4 count;
• Perform TB symptom screen; take sputum sample if
symptomatic and perform rapid TB test; initiate TB
treatment if required (ART initiation delayed if TB
treatment initiated;
• Perform other blood tests (rapid);
• Conduct physical exam (ART initiation delayed if
referred off site for specific conditions);
• Conduct education/adherence session;
• Conduct individual counseling session;
• Dispense ARVs
Visit 1
9. Results: Initiated ART ≤ 90 Days; Initiated ≤ 90 Days and
Retained and Virally Suppressed ≤ 10 Months
377 ART eligible patients enrolled
136 initiated ≤ 90 days (72%) 182 initiated ≤ 90 days (97%)
Risk difference 25% (95% CI 19 to 33%)
Crude relative risk 1.36 (95% CI 1.24 to 1.49)
54 did not initiate ≤ 90 days 5 did not initiate ≤ 90 days
96 initiated ≤ 90 days and
retained and suppressed by
10 months (51%)
119 initiated ≤ 90 days and
retained and suppressed by
10 months (64%)
Risk difference 13% (95% CI 3 to 23%)
Crude relative risk 1.26 (95% CI 1.05 to 1.5)
40 initiated but not retained
and suppressed
63 initiated but not retained
and suppressed
190 STANDARD arm patients 187 RAPID arm patients
10. What Did We Learn?
• Single-visit initiation as implemented by RapIT started
nearly all patients on ART and improved health outcomes
• But it relied on relatively expensive point-of-care
instruments and changed other resource allocation (e.g.
staff time)
• Is it cost-effective? Affordable?
• We conducted a cost-effectiveness analysis to compare
rapid to standard initiation
1 National Department of Health 2013; 2Plazy et al 2014; 3Clouse et al 2013; 4Rosen and Fox 2011; 5Larson et al 2010
12. Methods
Estimated cost per patient achieving primary outcome (initiated < 90 days and
retained and suppressed at 10 months) in each arm (“successful patient”)
Multiplied resources used per patient (from CRFs and clinic charts) by actual
unit costs for resources, to get an average cost per patient
- Clinic visits
- ARVs and non-ARV medications
- Laboratory tests (point of care and regular)
- Fixed costs of clinic infrastructure and staff
Three main results for each study arm:
- Cost per patient enrolled = total costs / total number of patients
- Cost per patient achieving primary outcome = costs for successful patients/
number of successful patients
- “Production cost” = all costs / number of successful patients
Scenario analyses to consider less expensive variations on the study algorithm
Report undiscounted provider costs in 2015 USD; excludes savings to patients
13. $319
$487
$738
$451
$505
$707
$0
$100
$200
$300
$400
$500
$600
$700
$800
Per patient enrolled Per patient suppressed Production cost
Costperpatientover10-monthperiodfollowingstudyenrollment
Standard arm, for comparison
Rapid arm baseline scenario
No POC TB tests (exclude patients
with TB symptoms)
Increase patient volume (implement
for all patients at clinic, not solely
study sample)
Shift task (some steps shifted from
primary health nurse to enrolled
nurse)
Minimum cost scenario: exclude TB
patients + high patient volume +
enrolled nurse
Results: Cost Per Outcome
$132
$18
-$31
14. What Did We Learn?
• Single-visit initiation as implemented by RapIT was both
more effective and more expensive than standard initiation
• Feasible variations on the RapIT strategy should reduce
costs, but they could also affect outcomes
• Is it cost-effective? It depends, but the POC instruments
are a deterrent
• Logical next step: Try the same strategy without the
technology
1 National Department of Health 2013; 2Plazy et al 2014; 3Clouse et al 2013; 4Rosen and Fox 2011; 5Larson et al 2010
16. SLATE: SimpLified Algorithm for Treatment Eligibility
• Evaluate a simple, fast procedure for determining eligibility for
immediate (same-visit) ART initiation without further steps
• Will enroll 960 adult patients presenting at clinics and not yet on ART in
South Africa and Kenya
• Randomize (1:1) to SLATE initiation v standard of care initiation
• Intervention: SLATE algorithm
- For those who “screen in,” immediate dispensing of ARVs at patient’s first
HIV-related clinic visit
- For those who “screen out,” refer for additional investigation, care,
counseling or support before dispensing ARVs
• Outcomes: ART initiation within 28 days; retention in care at 6 and 12
months
17. The SLATE Algorithm
Medical history
Brief physical exam
Screen out criteria = Cough, fever, night sweats, weight loss, persistent
headache, or serious self-reported symptoms suggesting further investigation
Screen out criteria = Observed conditions suggesting further investigation
Screen out criteria = Prior ART, TB treatment initiation <14 days, substance
abuse, or concurrent medications or conditions suggesting further care
Screen out criteria = Responses suggesting further counseling or support
Symptom report
Readiness
assessment
Continue
Continue
DISPENSE ARVS
Continue
REFER FOR FURTHER CARE BEFORE DISPENSING
18. SLATE (continued)
• After initiating ART under SLATE:
- Blood draw for required lab tests
- Schedule next routine visit
- Participate in clinic’s adherence support activities at this or future visit
• Study enrollment expected to start in February 2017 (South Africa) and
March 2017 (Kenya)
• Follow-up after enrollment visit is by chart review for up to 16 months
• Implemented by BU partners HE2RO in South Africa and KEMRI in
Kenya
• Funded by Bill & Melinda Gates Foundation
19. What Do We Hope to Learn?
• Does SLATE increase overall prompt uptake of ART, by
reducing loss to follow up between HIV testing and ART
initiation?
• Do patients initiated under SLATE have the same early
outcomes on ART as those initiated under standard care?
• What causes patients to “screen out” under SLATE?
• How much does ART initiation cost providers and patients
under SLATE compared to standard care?
• What are patients’ preferences for speed of initiation?
If successful, SLATE could help to standardize a fast,
effective, low-cost model of ART initiation, and strengthen
the cascade between testing and treatment.
1 National Department of Health 2013; 2Plazy et al 2014; 3Clouse et al 2013; 4Rosen and Fox 2011; 5Larson et al 2010
20. Thanks and Acknowledgements
Participants
• Study patients and study clinic operations managers and staff
• City of Johannesburg, Gauteng Department of Health, and Kenya Ministry of
Health
Collaborators
• HE2RO, Right to Care, KEMRI, Walter Reed Projects, Henry Jackson Foundation
• Co-investigators: At BU—Alana Brennan, Matt Fox, Bruce Larson; In South
Africa—Lawrence Long, Mhairi Maskew, Ian Sanne, Francois Venter, and team;
In Kenya—Isaac Tsikhutsu, Margaret Bii, and team
Funders
• NIH’s National Institute of Allergy and Infectious Diseases
• PEPFAR
• Bill & Melinda Gates Foundation